Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: A review

Diabetic Medicine

Volumn 25, Issue 10, 2008, Pages 1142-1150

  Lloret Linares, C ^a   Greenfield, J R ^b,c   Czernichow, S ^d,e,f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d Bioinformatique et Chimie Moléculaire   (France)

^e AVICENNE HOSPITAL   (France)

^f CRNH IdF 74 ^*  (France)

Author keywords

Diet; Drugs; Insulin; Obesity; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ARTHRALGIA; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIZZINESS; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MOOD CHANGE; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT MONITORING; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LACTONES; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 53349152409     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02550.x     Document Type: Review

References (58)

1. Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. Int J Obes Relat Metab Disord 2002 26 : 425 436.
2. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992 16 : 397 415.
3. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight non-diabetic spouses. Diabetes Care 1987 10 : 563 566.
4. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993 77 : 1287 1293.
5. UK Prospective Diabetes Study Group. UKPDS 24: a 6-year, randomized, controlled trial comparing sulphonylurea, insulin, and metformin therapy in patients with newly diagnosed Type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998 128 : 165 175.
6. Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006 29 : 1016 1023.
7. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with Type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004 89 : 6068 6076.
8. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994 56 : 82 85.
9. Clapham JC, Arch JR, Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 2001 89 : 81 121.
10. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003 27 : 289 301.
11. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001 410 : 822 805.
12. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005 29 : 183 187.
13. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003 284 : R345 353.
14. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A et al. Effects of weight loss with orlistat on glucose tolerance and progression to Type 2 diabetes in obese adults. Arch Intern Med 2000 160 : 1321 1326.
15. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005 142 : 547 559.
16. Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs 2006 66 : 1625 1656.
17. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005 65 : 1391 1418.
18. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004 CD004094.
19. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002 4 : 49 55.
20. Allison DB, Fontaine KR, Heshka S, Mentore JL, Heymsfield SB. Alternative treatments for weight loss: a critical review. Crit Rev Food Sci Nutr 2001 41 : 1 28 discussion 39-40.
21. Hollander PA. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diabetes Spectrum 2007 20 : 159 165.
22. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with Type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 CD004096.
23. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998 352 : 167 172.
24. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years' treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000 8 : 49 61.
25. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000 9 : 160 167.
26. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I on behalf on the orlistat and resistant hypertension investigators. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 20 : 2257 2267.
27. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002 56 : 494 499.
28. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care 2004 27 : 155 161.
29. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR et al. Weight reduction and long-term maintenance after 18 months' treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003 27 : 591 597.
30. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J Am Med Assoc 1999 281 : 235 242.
31. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicenter study of orlistat, a gatrointestinal lipase inhibitor. Int J Obes (Lond) 2000 24 : 306 313.
32. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001 50 : 505 512.
33. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005 353 : 2111 2120.
34. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000 356 : 2119 2125.
35. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 : 1389 1397.
36. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 353 : 2121 2134.
37. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006 295 : 761 775.
38. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 2006 368 : 1660 1672.
39. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated Type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 25 : 1033 1041.
40. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med 2005 22 : 612 68.
41. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M et al. Effect of orlistat in overweight and obese patients with Type 2 diabetes treated with metformin. Diabetes Care 2002 25 : 1123 1128.
42. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with Type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998 21 : 1288 1294.
43. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with Type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 4 : 415 423.
44. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese Type 2 diabetic patients treated with metformin. Diabetes Care 2003 26 : 125 131.
45. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult hispanic patients with Type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2004 26 : 1427 1435.
46. Chung JW, Suh KI, Joyce M, Ditzler T, Henry RR. Contribution of obesity to defects of intracellular glucose metabolism in NIDDM. Diabetes Care 1995 18 : 666 673.
47. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in Type 2 diabetes mellitus. Diabetes Obes Metab 2007 9 : 386 393.
48. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with Type 2 diabetes mellitus. Diabetes Obes Metab 2000 2 : 175 187.
49. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003 63 : 908 914.
50. Rissanen A, Lean M, Rossner S, Segal KR, Sjostrom L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003 27 : 103 109.
51. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004 64 : 2845 2864.
52. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE et al. Efficacy of orlistat as an adjunct to behavioural treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004 17 : 307 319.
53. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004 164 : 994 1003.
54. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007 28 : 2915 2923.
55. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007 370 : 1706 1713.
56. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
57. Redmon JB, Raatz SK, Reck KP, Swanson JE, Kwong CA, Fan Q et al. One-year outcome of a combination of weight loss therapies for subjects with Type 2 diabetes: a randomized trial. Diabetes Care 2003 26 : 2505 2511.
58. Redmon JB, Reck KP, Raatz SK, Swanson JE, Kwong CA, Ji H et al. Two-year outcome of a combination of weight loss therapies for Type 2 diabetes. Diabetes Care 2005 28 : 1311 1315.